AnaptysBio, Inc.

AnaptysBio, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. AnaptysBio, Inc. is not a good growth stock. AnaptysBio, Inc. is not very popular among insiders. AnaptysBio, Inc. is a mediocre stock to choose.

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody pro...

News

AnaptysBio, Inc. (NASDAQ:ANAB) Receives $50.30 Consensus Target Price from Brokerages

Zolmax Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven brokerages that are currently covering the stock, Marketbeat.com reports...\n more…

AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Ticker Report AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are presently covering the stock, MarketBeat...\n more…

AnaptysBio management to meet virtually with BTIG

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

AnaptysBio management to meet virtually with BTIG

Why AnaptysBio Was Such a Healthy Stock This Week

Fool.com Headlines Clinical-stage biotech AnaptysBio (NASDAQ: ANAB) has recently been something of a standout, at least on the stock exchange. According to data compiled by S&P Global Market Intelligence, the...\n more…